Porte, J.; Saint-Martin, C.; Frederic-Moreau, T.; Massiani, M.-A.; Bozec, L.; Cao, K.; Verrelle, P.; Otz, J.; Jadaud, E.; Minsat, M.;
et al. Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. Biomedicines 2022, 10, 2249.
https://doi.org/10.3390/biomedicines10092249
AMA Style
Porte J, Saint-Martin C, Frederic-Moreau T, Massiani M-A, Bozec L, Cao K, Verrelle P, Otz J, Jadaud E, Minsat M,
et al. Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. Biomedicines. 2022; 10(9):2249.
https://doi.org/10.3390/biomedicines10092249
Chicago/Turabian Style
Porte, Judith, Caroline Saint-Martin, Thomas Frederic-Moreau, Marie-Ange Massiani, Laurence Bozec, Kim Cao, Pierre Verrelle, Joelle Otz, Eric Jadaud, Mathieu Minsat,
and et al. 2022. "Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases" Biomedicines 10, no. 9: 2249.
https://doi.org/10.3390/biomedicines10092249
APA Style
Porte, J., Saint-Martin, C., Frederic-Moreau, T., Massiani, M.-A., Bozec, L., Cao, K., Verrelle, P., Otz, J., Jadaud, E., Minsat, M., Langer, A., Girard, N., Créhange, G., & Beddok, A.
(2022). Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. Biomedicines, 10(9), 2249.
https://doi.org/10.3390/biomedicines10092249
